Ceftriaxone in febrile neutropenia.
Standard management of febrile neutropenia requires prompt administration of empirical, broad-spectrum antibiotic therapy, since febrile neutropenia is associated with a significant risk of infectious complications and mortality. Risk-assessment models have been developed that differentiate febrile patients with neutropenia according to their risk for infectious complications and/or mortality and have prompted a change in the management of these patients. Ceftriaxone is a long-lasting, broad spectrum cephalosporin which has demonstrated efficacy in this indication in many publications. The role of ceftriaxone in febrile neutropenia will be discussed based on literature analysis and on the author's experience.
Karthaus
M
M
Med. Klinik II, Department of Oncology and Palliative Care, Evangelisches Johannes-Krankenhaus, Bielefeld, Germany. Meinolf-Karthaus@Johanneswerk.de
Cornely
O A
OA
D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D002443:Ceftriaxone / Q000008:administration & dosage*; D002511:Cephalosporins / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D005334:Fever / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D008297:Male; D009503:Neutropenia / Q000150:complications / Q000188:drug therapy*; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D002443:Ceftriaxone